Talon Capital
440 Louisiana Street, Suite 1050, Houston, Texas, 77002, United States
Overview
Talon Capital is a special-purpose acquisition company that focuses on the energy and power industries. The company seeks to identify and merge with businesses engaged in energy services and power solutions, leveraging its management team’s expertise to support growth, operational improvements, and strategic development after the initial business combination.
- Total investments
- 2
- Lead investments
- 0
- Investments · 12mo
- 2
- Active investors
- 0
Investment portfolio
- Oricell Therapeutics
Participated · Equity · Apr 2026
Oricell leverages a proprietary technology triad—Ori®Ab antibody discovery, Ori®Armoring T-cell enhancement, and OnGo CMC rapid manufacturing—to develop a diversified pipeline of cell therapies targeting solid tumors and hematologic malignancies. Its lead asset, Ori-C101, is a GPC3-targeted autologous CAR-T for advanced hepatocellular carcinoma that has completed investigator-initiated trials and a registrational Phase 1 and is preparing for pivotal trials, with clinical readouts highlighted at major forums including ASCO. Another core candidate, OriCAR-017, advanced from IIT in China to global development, securing IND approvals from China NMPA and the US FDA as well as FDA Orphan Drug and Fast Track designations. Oricell has presented data at multiple global conferences (including ASCO and EHA) and published results in The Lancet Haematology. The company states the programs have demonstrated favorable safety and robust efficacy in IIT and registrational trials, supporting its global regulatory and clinical strategy.
Team
No current team members are available.